NCT05074810 2026-01-12
RAMP203
Verastem, Inc.
Phase 1/2 Active not recruiting
Clinical Trials
6 trialsNCT02004028 2024-02-20
Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants
Verastem, Inc.
Phase 2 Terminated
NCT04620330 2024-01-12
RAMP202
Verastem, Inc.
Phase 2 Completed
NCT01951690 2017-04-13
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Verastem, Inc.
Phase 2 Completed
NCT01870609 2017-01-30
COMMAND
Verastem, Inc.
Phase 2 Terminated
NCT02372227 2017-01-30
A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
Verastem, Inc.
Phase 1 Terminated